《麻省理工科技评论》从 2013 年开始报道 CRISPR 基因编辑技术，我们将它称为本世纪最大的生物技术突破。然而到目前为止，只有一种基因编辑药物获批。这种药物仅在约 40 名患有镰状细胞病的患者身上进行了商业化使用。

If you are wondering whether CRISPR Therapeutics at about US$53.84 is still priced attractively or already baking in a lot of ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $53.84, demonstrating a -4.54% change from the preceding ...

Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Cathie Wood has seldom shied away from letting everyone know where she believes the next wave of market-changing businesses ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Friday, December 26, according to its daily fund ...

On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three ...

CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what ...

CRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...